DOD Peer Reviewed Cancer, Clinical Trial Award
Department of Defense
Description
The FY25 Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award aims to support clinical trials that could significantly impact cancer treatment or management. Eligible trials may evaluate new drugs, devices, clinical guidelines, or innovative approaches and can range from small initial trials to large-scale phase III trials. A clinical trial must be included in the application. An active Investigational New Drug Application (IND) or Investigational Device Exemption (IDE) is requ…
Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic …
Source
Grant ID
HT942525PRCRPCTA
Agency
Department of Defense
Subcategory/Subagency
Dept. of the Army -- USAMRAA
Eligibility
The following categories of applicants are invited to apply:
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Awards & Funding
Total Funding
$33.6M
Funding Amount
Discretionary
Links
Documents
Similar opportunities
- DOD Peer Reviewed Cancer, Impact Award
Department of Defense
- NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Department of Health and Human Services
- Facilitating Clinical Trials in Cancer Prevention and Control
National Institutes of Health
- Toward Translation of Cancer Nanotechnology Interventions (TTNCI)
National Institutes of Health
- Notice of Funding Opportunity (NOFO) for Early Phase Clinical Trials in Cancer Research
National Institutes of Health